Seer, Inc. (SEER)
Seer is a life-sciences instrumentation company that builds tools to decode the protein layer of human biology. Its flagship platform, Hyphenated Mass Spectrometry, enables researchers and clinicians to analyze thousands of proteins from tiny samples—blood, tissue, or cell lines—at a resolution that rival technologies cannot yet match. The company sells instruments, reagents, and software to academic and pharmaceutical research institutions, and it is building a services business that runs analyses directly for clinical and pharmaceutical clients. Seer’s shares trade on the NASDAQ under the ticker SEER.
The protein frontier
For decades, the highest resolution map of human biology was the genome—the three billion base pairs that define our inherited instructions. But DNA is the plan, not the outcome. Proteins are the actual machinery: they do the chemical work inside every cell, they signal between cells, they recognise and respond to disease. A person can have the exact same DNA as another person yet develop different diseases because their proteins behave differently—shaped by environment, age, diet, medication, prior infection. To predict and treat disease at the level of precision medicine demands, researchers must move beyond genes and sequence proteins instead.
Protein measurement was historically the domain of antibody-based assays—tools that grab one or a handful of proteins with high specificity but miss the vast majority of what is happening. In the early 2010s, a new generation of proteomics platforms began to change this. They could sense thousands of proteins in a single sample using mass spectrometry—a technique that ionises molecules and sorts them by mass and charge. Seer, founded by researchers at Stanford and Harvard, chose to push the boundaries of what mass spectrometry could do. Their insight was that by coupling sample preparation, liquid chromatography, and mass spectrometry into a tight pipeline, they could achieve a combination of sensitivity, throughput, and ease of use that no competitor had matched.
Unit economics: building a consumables engine
For Seer, the route to profitability mirrors many life-sciences instrument companies: sell the hardware at modest margins, then extract recurring revenue from the ongoing purchases of reagents, kits, and services that customers must buy to run the machine. This economics means the business cannot be profitable in the near term—each new instrument installed is years of support cost upfront before the consumables stream accumulates. It also means growth depends on two separate curves: the installed base of instruments, and the utilisation (number of samples run) on each one.
The company’s early revenue came almost entirely from instrument sales to academic research labs and pharmaceutical discovery teams, where the tool quickly became a reference standard for certain high-value protein-measurement tasks. As the installed base grew, consumables sales began to follow. In recent years, Seer has pushed into a services offering—running samples through its platform on behalf of clinical and pharma partners—which represents a much higher-margin revenue stream because Seer both controls the equipment and the supply chain and captures the full profit. The ambition is to become as much a discovery service company as an instrument company, with the hardware becoming the enabling layer rather than the primary revenue driver.
The competitive moat and what threatens it
Seer’s moat rests on the accuracy and usability of its platform. Achieving high sensitivity in mass spectrometry requires exquisite sample handling and instrument design, and Seer has the technical depth and patent position to lead. Rival companies and academic research groups have built alternative proteomics platforms—some focusing on aptamer selection, others on different MS approaches—but none has yet displaced Seer in the customers and applications where Seer leads. The larger threat is that mass spectrometry itself may not remain the highest-resolution protein-measurement technology indefinitely. Younger platforms like optical protein mapping and other emerging techniques could offer orthogonal or superior capabilities at lower cost.
The deeper structural risk is that Seer, like all early-stage biotech instrumentation companies, burns cash while building the installed base and relies on customers (research labs, pharmaceutical companies) continuing to fund basic discovery. A recession that dries up research budgets, or a shift in pharma away from target discovery toward internal algorithmic approaches, could sharply slow instrument demand. And because the services business is newer, if pharma clients in-source the work or turn to competing providers, Seer’s high-margin revenue stream could contract.
The path forward
Seer’s core challenge is not technical but commercial: growing the installed base fast enough that consumables and services revenue can absorb the overhead cost of supporting thousands of customers globally. The company has enough capital and a large enough addressable market—pharmaceutical and biotech spend tens of billions annually on discovery tools and services—that reaching profitability is plausible. But the company also competes for customer wallet in a crowded space, where adoption of any new platform requires persuading established research groups to change workflows that already work, even if imperfectly.
How to research Seer as an investment centres on understanding the pace of instrument placements, the utilisation trajectory on existing hardware, and the gross margins of the services business as it scales. The annual 10-K filing (SEC CIK 0001726445) breaks these out, and the quarterly earnings calls disclose the absolute number of installed systems and the consumables revenue per system, which is the clearest leading indicator of whether the business will eventually reach sustainable profitability. Watch too for competitive wins and losses in major pharmaceutical accounts, as these signal whether Seer’s technology is pulling away from alternatives or converging with them.